VivoSim Labs introduces AI-driven drug testing models

SAN DIEGO - VivoSim Labs, Inc. (NASDAQ:VIVS), a biotechnology firm with a market capitalization of $2.97 million, has announced the launch of its new approach methodologies (NAM) models designed to provide insights into liver and intestinal toxicology for drug discovery and development. According to InvestingPro data, the company’s stock has shown significant volatility, currently trading at $2.04. This move comes on the heels of the FDA’s April 10 announcement to gradually eliminate animal testing requirements in favor of non-animal NAM methods.

The FDA’s initiative is seen as a significant shift in drug evaluation, with the potential to expedite the delivery of safer treatments to patients while also reducing research and development costs. VivoSim’s models utilize AI-based computational modeling, human organ model-based lab testing, and real-world human data to predict liver toxicity, intestinal toxicity, and drug permeability.

The company claims its NAMkind liver model has demonstrated an industry-leading correlation rate with known clinical failures, suggesting a potential to reduce late-stage clinical trial failures and post-market drug withdrawals due to liver toxicity by at least 50%. While current revenue stands at $0.12 million, InvestingPro analysts forecast a substantial 168% revenue growth for FY2025, indicating potential market confidence in the technology’s commercial prospects. Similarly, its NAMkind intestine models aim to provide insights that are currently unavailable, potentially improving patient outcomes by addressing issues such as chemotherapy dosing and side effects.

VivoSim’s approach aligns with the FDA’s goals to minimize animal testing, offering a commercial solution that could transform the drug development process. By potentially halving the development cost per approved drug, VivoSim believes it can significantly impact the pharmaceutical industry.

The company’s proprietary methods and advanced capabilities are positioned to displace the use of animals in testing and offer superior outcomes for pharmaceutical clients and patients. VivoSim’s announcement is based on a press release statement and reflects the company’s forward-looking perspective, which is subject to risks and uncertainties as detailed in its filings with the SEC.

For more information on VivoSim Labs and its NAMkind services, visit their website at vivosim.ai. For comprehensive financial analysis and additional insights, including 16 more exclusive ProTips and detailed financial metrics, check out InvestingPro’s advanced analytics platform.

In other recent news, Organovo Holdings, Inc. has announced a significant corporate rebranding to VivoSim Labs, Inc., effective April 24, 2025. This change includes a new ticker symbol ’VIVS’ on the Nasdaq Capital Market, aligning with the company’s focus on 3D bioprinting technologies. Additionally, Organovo disclosed a preliminary cash balance of approximately $11.3 million as of March 31, 2025, with net cash usage for the fourth quarter estimated between $2.0 and $2.2 million. The company is also anticipating a potential $5 million milestone payment within the next 12 months related to a Phase 2 clinical trial. In another strategic move, Organovo announced a 1-for-12 reverse stock split to comply with Nasdaq’s minimum bid price requirement. This adjustment will not change the par value per share and aims to enhance the marketability of its common stock. The reverse stock split was authorized by stockholders in November 2024 and approved by the board in March 2025. These developments reflect Organovo’s ongoing efforts to maintain its Nasdaq listing and strengthen its market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.